U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Squamous Cell Carcinoma

MedGen UID:
1768820
•Concept ID:
C5419204
•
Neoplastic Process

Definition

Squamous cell carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK
Semin Oncol 2002 Oct;29(5 Suppl 14):18-30. doi: 10.1053/sonc.2002.35644. PMID: 12422310

Recent clinical studies

Etiology

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW
Pharmacoeconomics 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1. PMID: 30972702Free PMC Article
Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.
Finger PT, Chin KJ
Ophthalmic Plast Reconstr Surg 2012 Mar-Apr;28(2):85-9. doi: 10.1097/IOP.0b013e3182392f29. PMID: 22186988
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study
Am J Clin Oncol 2007 Aug;30(4):428-31. doi: 10.1097/COC.0b013e31803377c8. PMID: 17762444
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T
Jpn J Clin Oncol 2007 Jul;37(7):477-81. doi: 10.1093/jjco/hym059. PMID: 17720737
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS
J Clin Oncol 2005 Aug 20;23(24):5578-87. Epub 2005 Jul 11 doi: 10.1200/JCO.2005.07.120. PMID: 16009949

Diagnosis

Case Report: Intra-Tumoral Vaccinations of Quadrivalent HPV-L1 Peptide Vaccine With Topical TLR-7 Agonist Following Recurrence: Complete Resolution of HPV-HR-Associated Gynecologic Squamous Cell Carcinomas in Two Patients.
Reedy M, Jonnalagadda S, Palle K
Pathol Oncol Res 2021;27:1609922. Epub 2021 Dec 20 doi: 10.3389/pore.2021.1609922. PMID: 34987310Free PMC Article
Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA
Clin Cancer Res 2013 Jan 15;19(2):428-41. Epub 2012 Nov 27 doi: 10.1158/1078-0432.CCR-12-2505. PMID: 23186778

Therapy

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW
Pharmacoeconomics 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1. PMID: 30972702Free PMC Article
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML
Oral Oncol 2018 Jun;81:45-51. Epub 2018 Apr 17 doi: 10.1016/j.oraloncology.2018.04.008. PMID: 29884413Free PMC Article
Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.
Finger PT, Chin KJ
Ophthalmic Plast Reconstr Surg 2012 Mar-Apr;28(2):85-9. doi: 10.1097/IOP.0b013e3182392f29. PMID: 22186988
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA
Am J Med Sci 2010 Feb;339(2):148-51. doi: 10.1097/MAJ.0b013e3181c4bd91. PMID: 20087165
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK
Semin Oncol 2002 Oct;29(5 Suppl 14):18-30. doi: 10.1053/sonc.2002.35644. PMID: 12422310

Prognosis

Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.
Cabezas-Camarero S, Cabrera-Martín MN, Iglesias-Moreno MC, Pérez-Segura P
Anticancer Drugs 2024 Oct 1;35(9):875-877. Epub 2024 Jun 28 doi: 10.1097/CAD.0000000000001635. PMID: 38941120
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW
Pharmacoeconomics 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1. PMID: 30972702Free PMC Article
Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.
Finger PT, Chin KJ
Ophthalmic Plast Reconstr Surg 2012 Mar-Apr;28(2):85-9. doi: 10.1097/IOP.0b013e3182392f29. PMID: 22186988
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study
Am J Clin Oncol 2007 Aug;30(4):428-31. doi: 10.1097/COC.0b013e31803377c8. PMID: 17762444

Clinical prediction guides

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW
Pharmacoeconomics 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1. PMID: 30972702Free PMC Article
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML
Oral Oncol 2018 Jun;81:45-51. Epub 2018 Apr 17 doi: 10.1016/j.oraloncology.2018.04.008. PMID: 29884413Free PMC Article
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC
Cancer Chemother Pharmacol 2014 Jun;73(6):1227-39. Epub 2014 Apr 9 doi: 10.1007/s00280-014-2459-z. PMID: 24714973
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C
Int J Clin Oncol 2006 Dec;11(6):454-60. Epub 2006 Dec 25 doi: 10.1007/s10147-006-0610-5. PMID: 17180514

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...